CN101203228A - 用于抗组胺的含异荭草素的组合物 - Google Patents
用于抗组胺的含异荭草素的组合物 Download PDFInfo
- Publication number
- CN101203228A CN101203228A CNA2006800086720A CN200680008672A CN101203228A CN 101203228 A CN101203228 A CN 101203228A CN A2006800086720 A CNA2006800086720 A CN A2006800086720A CN 200680008672 A CN200680008672 A CN 200680008672A CN 101203228 A CN101203228 A CN 101203228A
- Authority
- CN
- China
- Prior art keywords
- isorientin
- extract
- histamine
- aloe
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title claims abstract description 123
- 229960001340 histamine Drugs 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- ODBRNZZJSYPIDI-UHFFFAOYSA-N 3',4',5,7-tetrahydroxy-6-C-glucopyranosylflavone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-UHFFFAOYSA-N 0.000 title abstract description 10
- PLAPMLGJVGLZOV-UHFFFAOYSA-N Epi-orientin Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-UHFFFAOYSA-N 0.000 title abstract description 10
- UYJGIAWJIRZBNU-UHFFFAOYSA-N isoorientin Natural products OCC1OC(C(O)C(O)C1O)c2cc(O)c(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4 UYJGIAWJIRZBNU-UHFFFAOYSA-N 0.000 title abstract description 10
- ODBRNZZJSYPIDI-VJXVFPJBSA-N isoorientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-VJXVFPJBSA-N 0.000 title abstract description 10
- WJJFWGUVMIUWGG-UHFFFAOYSA-N Stereolensin Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O WJJFWGUVMIUWGG-UHFFFAOYSA-N 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 15
- 206010020601 Hyperchlorhydria Diseases 0.000 claims abstract description 7
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 7
- 208000017520 skin disease Diseases 0.000 claims abstract description 7
- 208000012657 Atopic disease Diseases 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 235000011399 aloe vera Nutrition 0.000 claims description 19
- 241001116389 Aloe Species 0.000 claims description 18
- 230000008859 change Effects 0.000 claims description 13
- 230000004064 dysfunction Effects 0.000 claims description 13
- 241000544043 Blyxa aubertii Species 0.000 claims description 12
- 210000002615 epidermis Anatomy 0.000 claims description 10
- 238000002481 ethanol extraction Methods 0.000 claims description 9
- 229940069521 aloe extract Drugs 0.000 claims description 8
- 241000209094 Oryza Species 0.000 claims description 7
- 238000003808 methanol extraction Methods 0.000 claims description 7
- 206010022000 influenza Diseases 0.000 claims description 6
- 206010048768 Dermatosis Diseases 0.000 claims description 5
- 230000002052 anaphylactic effect Effects 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 4
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 6
- 235000017491 Bambusa tulda Nutrition 0.000 claims 6
- 241001330002 Bambuseae Species 0.000 claims 6
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 6
- 239000011425 bamboo Substances 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 208000026935 allergic disease Diseases 0.000 abstract description 4
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- 210000003630 histaminocyte Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001387 anti-histamine Effects 0.000 description 8
- 239000000739 antihistaminic agent Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- PEFNSGRTCBGNAN-UHFFFAOYSA-N nephrocizin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-UHFFFAOYSA-N 0.000 description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000036783 anaphylactic response Effects 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 241000745988 Phyllostachys Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102100021022 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000007880 Phyllostachys bambusoides Species 0.000 description 2
- 235000001550 Phyllostachys bambusoides Nutrition 0.000 description 2
- 235000017225 Phyllostachys nigra var henonis Nutrition 0.000 description 2
- 240000002014 Phyllostachys nigra var. henonis Species 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 241000267040 Sasa borealis Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004508 fractional distillation Methods 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- DEURIUYJZZLADZ-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)ethanamine Chemical class NCCC1=NC=CN1 DEURIUYJZZLADZ-UHFFFAOYSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000360771 Coreana Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000003915 Lophatherum gracile Species 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000511006 Oryza alta Species 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 240000002264 Phyllostachys aurea Species 0.000 description 1
- 235000010792 Phyllostachys aurea Nutrition 0.000 description 1
- 244000302661 Phyllostachys pubescens Species 0.000 description 1
- 235000003570 Phyllostachys pubescens Nutrition 0.000 description 1
- 241000400665 Pleioblastus gramineus Species 0.000 description 1
- 240000004971 Pseudosasa japonica Species 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- BQFCCCIRTOLPEF-UHFFFAOYSA-N chembl1976978 Chemical compound CC1=CC=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 BQFCCCIRTOLPEF-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 1
- 229940032712 succinylcholine Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 229960001844 tubocurarine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H39/04—Devices for pressing such points, e.g. Shiatsu or Acupressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0157—Constructive details portable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0192—Specific means for adjusting dimensions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/16—Physical interface with patient
- A61H2201/1683—Surface of interface
- A61H2201/169—Physical characteristics of the surface, e.g. material, relief, texture or indicia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/06—Arms
- A61H2205/065—Hands
- A61H2205/067—Fingers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Rehabilitation Therapy (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明涉及一种用于预防或治疗由组胺过度介导的疾病的药物组合物,该组合物含有天然衍生的异荭草素,本发明还涉及异荭草素用于制备预防或治疗由组胺过度介导的疾病药物的应用,本发明还涉及一种预防或治疗由组胺过度介导的疾病的方法,包括给予患者治疗有效量的异荭草素。本发明的组合物、应用及方法显示出良好的组胺抑制作用,可以用于预防或治疗各种过敏性疾病、特应性疾病、炎性疾病、皮肤病、胃酸过多症和神经***障碍。
Description
技术领域
本发明涉及一种用于预防或治疗由组胺过度介导的疾病的药物细合物,该组合物含有天然衍生的异荭草素作为活性成分,本发明还涉及异荭草素用于制备预防或治疗由组胺过度介导的疾病的药物的应用,本发明还涉及一种预防或治疗患者的由组胺过度介导的疾病的方法,包括给予患者治疗有效量的异荭草素。
背景技术
组胺是一种存在于血液和各种组织当中的生理活性物质。从结构上说,组胺还可归类于氨乙基咪唑类,其中咪唑环和胺基基团通过两个亚甲基基团相连。在几乎所有的动物的组织中都能够找到组胺,它甚至存在于各种毒素、细菌或植物当中。皮肤、支气管、肠粘膜等处含有丰富的组胺。在血液中,嗜碱性白细胞当中含有大量组胺。这些含有组胺的细胞可以通过L-组氨酸脱羧酶的作用从组氨酸合成组胺。表皮、胃粘膜、中枢神经***中的神经细胞等中的非肥大细胞也能够合成组胺。
在人体中,细胺的代谢有两条途径。
在主要的代谢途径中,咪唑环通过N-甲基转移酶的作用转变成N-甲基组胺,而后N-甲基组胺再通过amonoamine氧化酶的作用转变成N-甲基咪唑乙酸。
在另一条途径中,组胺通过非特异的二氨氧化酶进行氧化脱氨。组胺的代谢产物几乎是无活性的,通过尿排出体外。
已知组胺能够诱发过敏、胃酸分泌以及作为中枢神经***神经递质的功能[Corrado ME et a1.,Arzneimittelforschung,54(10)660-5,2004,Salmun LM.,Expert Opin Investig Drugs,11(2)259-73,2002,Scannell RT et al.,MiniRev Med Chem,4(9)923-33,2004,Kapp A et al.,J Drugs Dermatol.,3(6)632-9,200.Orzechowski RF等人的Eur J Pharmacol.,506(3)257-64,2005]。
首先,研究组胺在过敏反应中的作用,接触到抗原时,产生抗体(IgE),附着在肥大细胞和嗜碱性白细胞表面,通过膜磷酸化作用引起细胺释放。组胺是储存在肥大细胞中的最终形式。因此,当抗原与IgE抗体在肥大细胞表面相互作用时,组胺得以释放。磷脂酶A2同时被激活,生成血小板活化因子(PAF),或花生四烯酸的代谢产物如***素、白三烯D4等,并和组胺一同释放。
其次,迷走神经或胃泌素会加速胃酸的分泌,但是组胺是调节胃酸分泌的最重要的物质。当使用H2受体阻断剂时,通过乙酰胆碱或胃泌素的酸分泌以及通过组胺的酸分泌都被阻断。因此,认为组胺是生理酸分泌机制的最终调节者。
最后,研究中枢神经***中的组胺的作用,组胺的功能相当于神经递质。已知H1受体广泛分布在丘脑、下丘脑、小脑和前脑中。这些神经细胞调节体温、ADH分泌、血压、饮水等,所有这些都受H1和H2受体介导。
具有以上所述功能的组胺还通过各种药物以及炎症或过敏反应从肥大细胞中释放出来。在治疗药物中,各种生物碱如***、可待因阿托品等;抗生素;筒箭毒碱;琥珀胆碱;辐射对比介质;和血浆增容药如右旋糖酐、聚维酮等能引起组胺的释放。
组胺释放可以被cAMP增强药物如肾上腺素能激动药,各种酯酶抑制剂,能量产生酶抑制作用的物质(fluorine),糜蛋白酶抑制物等所抑制。色甘酸钠能使肥大细胞细胞膜稳定,可抑制组胺和白三烯D4在支气管粘膜中的释放,可用于预防支气管哮喘的发作。
因此,组胺在过敏反应中是主要的调节介质,单独或与其它因素共同起作用于哮喘、鼻炎和皮肤病例如荨麻疹和特应性皮炎[Scannell RT et al.,MiniRev Med Chem.,4(9)923-33,2004,Imaizumi A et al.,J Dematol Sci.,33(1)23-9,2003,Kapp A et al.,J Drugs Dermatol.,3(6)632-9,2004]。而且,组胺会引起感冒、恶心和呕吐、胃酸过多症、食管反流、十二指肠溃疡、炎症,和低体温症以及与过敏反应有关的低血压[Latsen JS.,Pharmacotheraphy,21:28S-33S,2001.,Leurs R.,Cl in Exp Allergy 32(4)489-98,2002.,Makabe-Kobayashi Y et al.,J Allergy Clin Immunol.,110(2)298-303,2002.]。为预防或治疗这些疾病,已开发了许多药物,包括苯海拉明、曲吡那敏、氯苯那敏、氯苯甲嗪、异丙嗪、阿司咪唑等,最近报导这些药物可用于神经保护(痴呆)和认知功能增强[Bachurin S et al.,Ann NY Acad Sci.,939:424-35.,2001.,Nakazato Eet al.,Life Sci.,67(10)1139-47,2000.]。
本发明的发明者继续研究天然的产品以发现具有抗组胺活性的物质。结果发现,芦荟、竹类植物、稻类植物等具有抗组胺活性,并且鉴定出从这些天然物质中分离出的活性成分是异荭草素,得以完成本发明。
发明概述
本发明的一个目的是提供一种预防或治疗由组胺过度引起的生理改变或功能障碍介导的疾病的药物组合物,该组合物含有天然衍生的异荭草素。
本发明的另一个目的是提供一种天然衍生的异荭草素用于制备预防或治疗由组胺过度引起的生理改变或功能障碍介导的疾病的药物的应用。
本发明还一个目的是提供一种预防或治疗患者由组胺过度引起的生理改变或功能障碍介导的疾病的方法,包括给予患者治疗有效量的天然衍生的异荭草素。
附图说明
图1.是异荭草素的1H-NMR图谱
图2.是异荭草素的13C-NMR图谱
图3.是异荭草素的阴性HPLC ESI-MS图谱
发明详述
为达到上述的目的,本发明提供了一种预防或治疗由组胺过度引起的生理改变或功能障碍介导的疾病的药物组合物,该组合物含有天然衍生的异荭草素作为活性成分。
本发明还提供了一种天然衍生的异荭草素用于制备预防或治疗由组胺过度引起的生理改变或功能障碍介导的疾病的药物的应用。
本发明还提供了一种预防或治疗患者由组胺过度引起的生理改变或功能障碍介导的疾病的方法,包括给予患者治疗有效量的天然衍生的异荭草素。
在本发明中,“由组胺过度引起的生理改变或功能障碍介导的疾病”指的是过敏性疾病、哮喘、鼻炎、特应性疾病、皮肤病、感冒、胃酸过多症、食管反流、十二指肠溃疡、炎症,和神经***障碍,包括特应性皮炎、荨麻疹、哮喘、疾呆等。
在本发明中,“过敏性疾病”指的是荨麻疹、恶心、呕吐、特应性皮炎、过敏反应、哮喘、鼻炎等,“神经***障碍”指的是痴呆、认知功能下降等。
在本发明中,优选含有异荭草素的组合物特别是芦荟、竹类植物或稻类植物的提取物。
优选的是,所述含有异荭草素的芦荟、竹类植物或稻类植物的提取物是,但不限于,水提取物,或C1-4的醇如甲醇、乙醇、丙醇、丁醇等的提取物,或这些的混和溶剂提取物。特别是,含有异荭草素的芦荟提取物优选通过30-80%的甲醇或乙醇对芦荟进行提取获得。含有异荭草素的竹类植物优选通过用水提取竹类植物得到脱水提取物后,再用甲醇或乙醇提取脱水提取物获得的。提取物包括全部提取物和它的级分。另外,含有异荭草素的芦荟提取物优选但不限于由芦荟表皮提取得到。
本发明的组合物可以通过常规的制药学领域的方法制备成常规的药物制剂,例如,溶液剂如饮剂、糖浆剂、胶囊剂、颗粒剂、片剂、散剂、丸剂、软膏剂、乳剂、凝胶剂、皮肤外用剂如乳油等,制备中可任选与药学可接受的载体、赋形剂等混合;制剂可以口服或非胃肠道给药。优选的是,本发明的组合物以胶囊、片剂和饮剂形式在饭前或饭后口服给药,以达到快速起效的效果。
含有本发明组合物的胶囊、片剂、散剂、颗粒剂、溶液剂、丸剂、凝胶剂等优选用作药品或保健产品。在本发明中,“保健产品”指的是应用对人体有益的原料或成分制成片剂、胶囊、散剂、颗粒剂、溶液剂、丸剂、凝胶剂等的食物产品。
本发明的组合物的适当给药依赖于活性成分在体内的吸收程度、患者的***速率、年龄、体重、性别和健康状况,疾病的严重程度等。然而,一般地,本发明的组合物优选的给药是成年人每天0.01-500mg/kg,优选是每天0.1-200mg/kg,每天1-3次。
在下文中,本发明将以参照下面的实施例和实验例的方式对发明进行详细描述,但是本发明的范围并不以任何方式受到限制。
实施例1:异荭草素的提取和鉴定
1.抗组胺活性成分的分离
本发明试图选择天然产物的提取物中产率和活性最佳的级分,并从级分中分离出抗组胺活性成分。天然产物的提取物减压蒸馏,用少量水溶解。然后,提取物用等量的CH2Cl2分馏,去除非极性物质,再用等量的BuOH分馏。异荭草素在BuOH层,BuOH层减压蒸馏,走二氧化硅柱。流动相为CHCl3、MeOH和水的混和溶剂,初始比率CHCl3∶MeOH∶水为7∶3∶1,直到6∶4∶1。
二氧化硅柱中的级分中,含有异荭草素的级分减压蒸馏,再走SephadexLH20柱。用100%的MeOH为洗脱液。在Sephadex LH20柱级分中,用TLC和HPLC检验,得到异荭草素。
2.活性成分的鉴定
C21H22O11的黄色粉末;1H-NMR(300MHz,d6-DMSO)及13C-NMR(75MHz,d6-DMSO)的数据与对照进行比较。参见Biosci.Biotechnol.Biochem.,67(2),410-414,2003。
经体外检验分析,通过活性追踪,具有抗组胺活性的化合物从芦荟、稻类植物及竹类植物级分中分离出来。使用NMR分光仪鉴定所分离的化合物的结构。在1H-NMR谱(图1和表1)中,一个质子的单峰在δ13.64ppm,在这一区域的多数峰都由于氢键而向低磁场区位移。在δ7.47ppm,与邻位δ6.97ppm邻位偶合而形成二重峰(J=8.3Hz),与δ7.45ppm间位偶合而形成二重峰(J=2.2Hz)。另外,一个质子的单峰分别在δ6.72ppm和δ6.53ppm。在δ4.65ppm,典型的端基质子作为二重峰具有偶联常数J=9.8Hz,因此确定结合有葡萄糖。
在13C-NMR谱(图2)中,共有21个碳原子,特别是在δ182.1ppm的羰基碳,和δ73.5ppm的端基碳。在阴性HPLC ESI-MS谱(图3)中,母离子峰在m/z 487处,预期的分子量为m/z 488。
表1
异荭草素的1H和13C NMR中的化学位移
Posbilon | HT ppm)ψ | Referenee ppm)ψ | ||
1H ppm) | 13C ppm) | 1H ppm) | 13C ppm) | |
42768*4*3*1*0*6*2*54*345*3*1*2*4*6* | 13.64(1Hg5-OH7.47(1H dd.J 83 22Hz6.87(1H dJ 83 Hz7.45(1H dJ 22 Hz6.72(1Hz6.53(1Hz4.65(1H dJ 86Hz | 182.0183.8183.9181.1156.7160.7148.4121.4119.3116.5113.4100.4103.2102.994.181.879.473.671.070.661.8 | 13.53(1Hz6-OH7.42(1H dJ 78Hz6.89(1H dJ 78Hz7.41(1Hz5.67(1Hz6.53(1Hz4.62(1H dJ 96Hz | 182.3164.2164.1161156.8150.3148.2121.8119.5116.6113.6108.2103.7103.294.281.878.373.870.970.751.9 |
根据上述的仪器分析结果和相关的参考资料[Abdul Mun’IM,OsamuNegishi,and Testuo Ozawa.(2003),Antioxidative Compounds fromCrotalaria sessiliflora.,Biosci.Biotechnol.Biochem.,67(2),410-414],从提取物中分离的具有抗组胺活性的化合物鉴定为异荭草素。
实施例2:含有异荭草素的植物的寻找,以及含量分析
在上述的实施例1中,可以确定异荭草素具有抗组胺活性。因此,在本实施例中,对申请人拥有的一些植物提取物进行分析。下表2显示植物提取物和其中异荭草素的含量。
为分析这些提取物,使用HITACHI***(泵:L-7100,检测器:L-7455,接口:D--7000,色谱分析柱加热器:L-7300,自动采样器:L-7200)作HPLC,分析条件为固定相为Phenomenex C18 4.6×250mm;流动相为梯度洗脱(溶剂A:乙腈,溶剂B:0.1%H3PO4的水溶液);洗脱速度为1.5mL/min;总分析时间为85分钟;柱温为35℃;样本浓度为50,000ppm;进样量为10μl;UV检测器使用330nm。
表2
植物中的异荭草素含量分析(成分含量%/产率%)
植物名称 | 异荭草素含量%/产率% |
Phyllostachys nigra var.henonis | 0.31/9.9 |
Phyllostachys pubscense | 0.25/10.97 |
Phyllostachys bsmbusoides | 0.4/11.69 |
Sasa coreana | 0.08/8.82 |
Sasa borealis | 0.52/14.2 |
Oryza alta | 0.49/13.8 |
Phyllostachys heterocycla var.pubescens | 0.8/11.3 |
Phyllos tachy nigra | 0.46/10.9 |
Phyllostachys nigra var.henonis Stapf | 0.62/10.4 |
Phyllostachys bambusoides var.Castillonis-inversa Houzeau de Lehaie | 0.39/10.7 |
Arundinaria graminea Makino | 1.05/11.9 |
Phyllostachys aurea Carriere exA.Riviere et C.Riviera | 0.26/10.3 |
Phyllostachys bambusoides var.tanakaeMakino | 0.18/8.7 |
Pseudosasa japonica | 0.19/7.38 |
Sasa borealis var.gracilis | 0.23/6.36 |
Lopha therum gracile | 0.24/10 |
aloe vera | 0.18/25 |
实施例3:芦荟中含高含量异荭草素的级分的制备
1kg芦荟真皮用15L 95%、80%、70%、60%、50%、40%或30%的乙醇提取,减压蒸馏得到水合提取物。所得提取物中的异荭草素含量用同上述的实施例2相同的方式用HPLC分析。结果显示,在50%乙醇提取物中异荭草素含量最高。
表3
芦荟不同部位在提取溶剂的不同乙醇量下提取的异荭草素含量和产率
部位 | 提取溶剂 | 异荭草素产量%/产率% |
表皮 | 95%乙醇 | 0.15/2.9 |
80%乙醇 | 0.38/3.4 | |
70%乙醇 | 0.53/4.1 | |
60%乙醇 | 0.82/4.8 | |
50%乙醇 | 1.2/5.4 | |
40%乙醇 | 0.73/6.4 | |
30%乙醇 | 0.27/7.8 | |
胶 | 95%乙醇 | 0.03/9.9 |
80%乙醇 | 0.08/10.97 | |
70%乙醇 | 0.13/11.69 | |
60%乙醇 | 0.15/15.2 | |
50%乙醇 | 0.05/36.7 | |
40%乙醇 | 0.01/41.4 | |
30%乙醇 | 0.01/62.3 |
实施例4:竹类植物中含高含量异荭草素级分的制备
10kg竹叶用150L水在80℃下提取8小时,减压蒸馏得到680g提取物。500g含水提取物用4L乙醇在70℃下提取2小时,冷却至室温,过滤。滤液减压蒸馏得到127g浓缩的提取物。100g浓缩提取物中加入800ml水,在80℃下提取2小时,后过滤。滤液冻干,得到61g含水提取物。
用实施例2相同的分析方法进行HPLC分析,显示异荭草素含量为3.2%。
实验例1:异荭草素的组胺释放抑制活性的测定
1.豚鼠肺肥大细胞的纯化
从8只豚鼠(雌性,200g)分离出肺组织(3g/只),去除脂肪组织、支气管和血液,通过含有Ca2+、Mg2+和0.1%的明胶的Tyrode缓冲液(TGCM缓冲液)用酶(5mg/ml胶原酶,1.8单位/27μl弹性蛋白酶)处理三遍,分别用时15分钟,15分钟和25分钟。每次酶处理过程中,肺组织用尼龙过滤网和金属过滤网(100μm)过滤,并离心分离(称为单分散肥大细胞)。丸状沉淀物悬浮在16ml含有Ca2+、0.1%的明胶,不含Mg2+的缓冲液(TG缓冲液)中,装载成粗硅石胶态悬浮液(Percoll)(1.041mg/ml密度),并在1400rpm转速下离心25分钟,得到丸状沉淀物。细胞再在8ml的TG缓冲液中悬浮,装载成间断型硅石胶态悬浮液(Percoll)(1.06-1.10mg/ml密度),并在1400rpm转速下再次离心25分钟,得到各种细胞层。在它们当中,肥大细胞主要存在于第三和第四层,得自这些层中的细胞用TGCM缓冲液洗涤两次。总细胞和肥大细胞分别用台盼蓝和阿辛蓝染色,通过显微镜测量细胞数以确定肥大细胞的纯度,纯度确定大约为80-90%。
2.用抗原/抗体反应分析肥大细胞中组胺的释放
肥大细胞(4×105个细胞)用豚鼠IgG1抗体(抗-OVA 1ml/106个细胞)处理,在37℃下反应45分钟,然后用TGCM缓冲液洗涤,去除掉没有结合到肥大细胞膜上的抗-OVA抗体。细胞在1ml TGCM缓冲液中悬浮,对每个浓度用药物(试验物质)处理5分钟。悬浮液用1.0μg/ml的卵清蛋白(OVA)致敏,反应10分钟,用冰冷却,离心分离。离心后,检测上清液的组胺。
每个样品中释放的组胺的量可使用自动恒流提取和荧光分析仪(Astoria分析仪300型,Astoria-pacific international,Oragon,USA)检测,并由Siraganian的方法(1)进得修正。准备好1N盐酸,0.73M磷酸,5N氢氧化钠,1N氢氧化钠,盐稀释剂和进样器洗剂,以及o-苯二醛溶液,连接好与分析仪相连接的管,稀释组胺储备液到20ng、10ng、5ng、3ng、1ng,得到浓度依赖性结果的标准曲线。每个样品用2%的高氯酸稀释以检测组胺含量。每个样品中的组胺含量用如下公式计算,为相对于在总细胞中的组胺含量的百分数。
*组胺含量=(样品中细胺释放量-自身释放量)/(总组胺释放量-自身释放量)×100
上述的检测结果见表4。研究从天然产品中分离的异荭草素的抗组胺活性,可以确定异荭草素通过浓度依赖方式抑制肥大细胞中的组胺释放,IC50值为30μg。
表4
异荭草素对由1.0μg/4×105细胞a活化而被动致敏(抗OVA抗体)的肺肥大细胞中组胺释放的影响。
样品名称 | 细胺(%) |
OVA | 32.5±0.86 |
异荭草素(1.25μg) | 27.9±2.62(14)** |
异荭草素(2.5μg) | 25.6±1.49(21.3)** |
异荭草素(5μg) | 21.9±2.01(32.6)* |
异荭草素(10μg) | 17.2±1.07(47.2)** |
实施例3的95%乙醇的表皮提取物(50μg) | 24.7±1.75(24.0)** |
实施例3的70%乙醇的表皮提取物(50μg) | 15.2±0.93(53.2)*** |
实施例3的50%乙醇的表皮提取物(50μg) | 5.2±0.43(84.0)** |
实施例3的30%乙醇的表皮提取物(50μg) | 20.4±1.75(37.2)** |
实施例4的竹类植物提取物(50μg) | 19.2±0.82(40.9)** |
实施例4的竹类植物提取物(100μg) | 3.2±0.52(90.15)** |
a豚鼠肥大细胞通过酶消化作用,走粗硅石胶态悬浮液和间断型硅石胶态悬浮液的密度梯度方法分离,纯化。肥大细胞(4×105细胞)由抗OVA抗体被动致敏,并由1.0μg/ml的OVA攻击。异荭草素在抗原攻击前5分钟加入。上清液中的组胺通过荧光分析仪测定。
b组胺释放的量用占总组胺量的百分数表示。圆括号表示用UG4-92预处理后的减少的百分数。
*p<0.05;**p<0.01;***p<0.001,与单独使用OVA相比。
():抑制%
制剂实施例1:溶液剂的制备
异荭草素 1g
糖 10g
异构化的糖 10g
柠檬调味剂 适量
加入纯净水后的总量 100ml
上述成分用常规制备溶液剂的方法混合,灭菌后得到溶液。
制剂实施例2:胶囊的制备
异荭草素 500mg
乳糖 50mg
淀粉 50mg
滑石粉 2mg
硬脂酸镁 适量
上述成分用常规制备胶囊的方法混合,填充至明胶胶囊中,得到胶囊。
工业实用性
本发明的含有异荭草素的组合物,异荭草素的用途,应用异荭草素预防或治疗的方法显示良好的组胺抑制效果,可以用于预防或治疗各种过敏性疾病、特应性疾病、皮肤病、感冒、胃酸过多症和神经***障碍。
Claims (18)
1.一种用于预防或治疗由组胺过度引起的生理改变或功能障碍介导的疾病的药物组合物,含有天然衍生的异荭草素作为活性成分。
2.如权利要求1所述的组合物,其中由组胺过度引起的生理改变或功能障碍介导的疾病是过敏性疾病、特应性疾病、皮肤病、感冒、胃酸过多症或神经***障碍。
3.如权利要求1所述的组合物,其中含有天然衍生的异荭草素的组合物是芦荟、竹类或稻类植物的提取物。
4.如权利要求3所述的组合物,其中含有异荭草素的芦荟提取物通过用30-80%的甲醇或乙醇提取芦荟获得。
5.如权利要求3所述的组合物,其中含有异荭草素的竹类提取物通过用水提取竹类植物得到脱水提取物,再用甲醇或乙醇提取该脱水提取物获得。
6.如权利要求3或4所述的组合物,其中含有异荭草素的芦荟提取物从芦荟表皮获得。
7.天然衍生的异荭草素用于制备预防或治疗由组胺过度引起的生理改变或功能障碍介导的疾病的药物的应用。
8.如权利要求7所述的应用,其中由组胺过度引起的生理改变或功能障碍介导的疾病是过敏性疾病、特应性疾病、皮肤病、感冒、胃酸过多症或神经***障碍。
9.如权利要求7所述的应用,其中天然衍生的异荭草素是芦荟、竹类或稻类植物的提取物。
10.如权利要求9所述的应用,其中含有异荭草素的芦荟提取物通过用30-80%的甲醇或乙醇提取芦荟获得。
11.如权利要求9所述的应用,其中含有异荭草素的竹类提取物通过用水提取竹类植物得到脱水提取物,再用甲醇或乙醇提取该脱水提取物获得。
12.如权利要求9或10所述的应用,其中含有异荭草素的芦荟提取物从芦荟表皮获得。
13.一种预防或治疗患者由组胺过度引起的生理改变或功能障碍介导的疾病的方法,包括给予患者治疗有效量的天然衍生的异荭草素。
14.如权利要求13所述的方法,其中由组胺过度引起的生理改变或功能障碍介导的疾病是过敏性疾病、特应性疾病、皮肤病、感冒、胃酸过多症或神经***障碍。
15.如权利要求13所述的方法,其中天然衍生的异荭草素是芦荟、竹类或稻类植物的提取物。
16.如权利要求15所述的方法,其中含有异荭草素的芦荟提取物通过用30-80%的甲醇或乙醇提取芦荟获得。
17.如权利要求15所述的方法,其中含有异荭草素的竹类提取物通过用水提取竹类植物得到脱水提取物,再用甲醇或乙醇提取该脱水提取物获得。
18.如权利要求15或16所述的方法,其中含有异荭草素的芦荟提取物从芦荟表皮获得。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050022772 | 2005-03-18 | ||
KR1020050022772A KR100720973B1 (ko) | 2005-03-18 | 2005-03-18 | 천연물 유래 아이소오리엔틴을 포함하는 히스타민 억제용약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101203228A true CN101203228A (zh) | 2008-06-18 |
Family
ID=36992143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800086720A Pending CN101203228A (zh) | 2005-03-18 | 2006-03-17 | 用于抗组胺的含异荭草素的组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20080214658A1 (zh) |
EP (1) | EP1863498A2 (zh) |
JP (1) | JP2008533131A (zh) |
KR (1) | KR100720973B1 (zh) |
CN (1) | CN101203228A (zh) |
AU (1) | AU2006223734B2 (zh) |
BR (1) | BRPI0608546A2 (zh) |
CA (1) | CA2601046A1 (zh) |
WO (1) | WO2006098603A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101843612A (zh) * | 2010-05-21 | 2010-09-29 | 暨南大学 | 异荭草苷作为制备抗呼吸道合胞病毒的药物的用途 |
CN102285976A (zh) * | 2011-09-27 | 2011-12-21 | 天津市尖峰天然产物研究开发有限公司 | 从竹叶黄酮中提取异荭草素的方法 |
CN102743375A (zh) * | 2012-04-28 | 2012-10-24 | 苏州凯祥生物科技有限公司 | 异荭草素的用途及其药物组合物 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7108868B2 (en) | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
ES2330097T3 (es) | 2002-04-30 | 2009-12-04 | Unigen Pharmaceuticals, Inc. | Formulacion de una mezcla de flavanos y flavonoides de anillo b libre como un agente terapeutico. |
US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
JP4684893B2 (ja) * | 2003-03-27 | 2011-05-18 | ユニジェン インク. | 炎症性及び血液循環疾患の治療及び予防活性を示す、竹抽出物並びにそれから分離された化合物を含有する組成物 |
CN1798568B (zh) | 2003-04-04 | 2011-05-11 | 尤尼根制药公司 | 用于哺乳动物皮肤护理的双重环氧合酶(cox)以及脂氧合酶(lox)抑制剂的组合物 |
KR100720971B1 (ko) * | 2004-06-11 | 2007-05-22 | 주식회사 유니젠 | 대나무 또는 대나무 추출물을 포함하는 안드로젠 효능성조성물 |
JP2007045755A (ja) * | 2005-08-10 | 2007-02-22 | Kameda Seika Co Ltd | 美白剤、抗アレルギー剤及び食料品 |
KR100761248B1 (ko) * | 2006-10-12 | 2007-10-04 | 주식회사 유니젠 | 대나무 및 황금 추출물을 유효성분으로 함유하는 아토피성피부염 치료를 위한 조성물 |
KR101050129B1 (ko) * | 2008-06-18 | 2011-07-19 | 주식회사 한국인삼공사 | 알레르기 질환 예방 또는 치료용 조성물 |
KR101702056B1 (ko) * | 2009-11-16 | 2017-02-03 | 주식회사 유니베라 | 피부세포증식 촉진, 항산화 및 항알러지 효과가 우수한 알로에 베라 새순 농축물 또는 추출물 |
FR2956324A1 (fr) * | 2010-01-18 | 2011-08-19 | Valerie Baille | Complexe vegetal comprenant un extrait polyphenolique de bambou |
KR20150019505A (ko) | 2013-08-14 | 2015-02-25 | 대화제약 주식회사 | 플라본-6-c-글루코스 유도체를 유효성분으로 함유하는 신경정신질환의 치료 또는 예방용 약학적 조성물 |
KR102488562B1 (ko) * | 2020-11-02 | 2023-01-12 | 인천대학교 산학협력단 | 갯끈풀 추출물을 유효성분으로 포함하는 염증 또는 아토피 피부염의 개선, 예방 또는 치료용 조성물 |
KR102543123B1 (ko) * | 2021-05-27 | 2023-06-13 | 주식회사 유니베라 | 알로에 꽃 추출물을 유효성분으로 함유하는 피부 보습용 조성물 |
WO2022250313A1 (ko) * | 2021-05-27 | 2022-12-01 | 주식회사 유니베라 | 알로에 베라 꽃 추출물, 또는 알로에 베라 꽃 추출물 및 알로에 베라 다당체를 유효성분으로 함유하는 피부 보습, 재생 촉진 및 상처 치료용 조성물 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4201776A (en) * | 1977-01-31 | 1980-05-06 | The Green Cross Corporation | Food additive for reinforcing foods deficient in fiber content |
US5106616A (en) * | 1988-01-14 | 1992-04-21 | Carrington Laboratories, Inc. | Administration of acemannan |
US5308838A (en) * | 1982-05-07 | 1994-05-03 | Carrington Laboratories, Inc. | Uses of aloe products |
JPS61233627A (ja) * | 1985-04-10 | 1986-10-17 | Agency Of Ind Science & Technol | 肥満細胞脱顆粒抑制剤 |
US5098709A (en) * | 1987-07-21 | 1992-03-24 | Kang Kwon J | Method of administrating a fused salt from natural substances, namely ginkgo, persimmon, pine, and bamboo in the treatment of inflammations |
JPH05271090A (ja) * | 1991-12-27 | 1993-10-19 | Ruibosuteii Japan:Kk | 活性酸素消去・除去剤 |
JPH05271088A (ja) * | 1991-12-27 | 1993-10-19 | Ruibosuteii Japan:Kk | 皮膚疾患・免疫反応による組織障害改善治療剤 |
JPH06199690A (ja) * | 1992-03-06 | 1994-07-19 | Yunie:Kk | 脳代謝促進・脳機能改善剤 |
JP3811198B2 (ja) * | 1993-11-17 | 2006-08-16 | 株式会社創研 | 米からの抗アレルギー剤 |
TW235922B (en) * | 1994-07-06 | 1994-12-11 | Amboo Devise Co Ltd | A production process of deodorant |
JPH0840923A (ja) * | 1994-07-28 | 1996-02-13 | Masatoshi Nakano | 栄養補助剤 |
JPH1171292A (ja) | 1997-08-29 | 1999-03-16 | Masatoshi Nakano | 皮膚外用剤 |
WO2001007008A1 (en) * | 1999-07-23 | 2001-02-01 | E-L Management Corporation | Compositions containing mimosa phenolic compounds |
WO2001076614A1 (fr) * | 2000-04-10 | 2001-10-18 | Takara Bio Inc. | Remedes |
US20030203857A1 (en) * | 2000-04-11 | 2003-10-30 | Hiromu Ohnogi | Remedies |
US20030170186A1 (en) * | 2000-04-18 | 2003-09-11 | Bernadette Geers | Novel flavone glycoside derivatives for use in cosmetics, pharmaceuticals and nutrition |
US20020146467A1 (en) * | 2001-02-08 | 2002-10-10 | Jung Kyu Yong | Herbal composition for the prevention and treatment of dementia |
US20040185124A1 (en) * | 2002-10-24 | 2004-09-23 | Hiromichi Hayashi | Health food and antitumor agent |
US20030125264A1 (en) * | 2001-12-29 | 2003-07-03 | Kimberly-Clark Worldwide, Inc. | Methods For Treating Wounds |
JP2003212786A (ja) * | 2002-01-16 | 2003-07-30 | Univ Nihon | 竹の抽出成分を有効成分とする皮膚外用薬 |
JP4684893B2 (ja) * | 2003-03-27 | 2011-05-18 | ユニジェン インク. | 炎症性及び血液循環疾患の治療及び予防活性を示す、竹抽出物並びにそれから分離された化合物を含有する組成物 |
CN1528197A (zh) * | 2003-10-08 | 2004-09-15 | ƽ | 竹叶抗氧化物及其用途 |
AU2005310314B2 (en) * | 2004-04-08 | 2011-07-21 | Corteva Agriscience Llc | Insecticidal N-substituted sulfoximines |
KR100720971B1 (ko) * | 2004-06-11 | 2007-05-22 | 주식회사 유니젠 | 대나무 또는 대나무 추출물을 포함하는 안드로젠 효능성조성물 |
KR100761248B1 (ko) * | 2006-10-12 | 2007-10-04 | 주식회사 유니젠 | 대나무 및 황금 추출물을 유효성분으로 함유하는 아토피성피부염 치료를 위한 조성물 |
-
2005
- 2005-03-18 KR KR1020050022772A patent/KR100720973B1/ko not_active IP Right Cessation
-
2006
- 2006-03-17 WO PCT/KR2006/000984 patent/WO2006098603A2/en active Application Filing
- 2006-03-17 CA CA002601046A patent/CA2601046A1/en not_active Abandoned
- 2006-03-17 US US11/908,927 patent/US20080214658A1/en not_active Abandoned
- 2006-03-17 AU AU2006223734A patent/AU2006223734B2/en not_active Expired - Fee Related
- 2006-03-17 BR BRPI0608546-6A patent/BRPI0608546A2/pt not_active IP Right Cessation
- 2006-03-17 JP JP2008501819A patent/JP2008533131A/ja active Pending
- 2006-03-17 EP EP06716434A patent/EP1863498A2/en not_active Withdrawn
- 2006-03-17 CN CNA2006800086720A patent/CN101203228A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101843612A (zh) * | 2010-05-21 | 2010-09-29 | 暨南大学 | 异荭草苷作为制备抗呼吸道合胞病毒的药物的用途 |
CN102285976A (zh) * | 2011-09-27 | 2011-12-21 | 天津市尖峰天然产物研究开发有限公司 | 从竹叶黄酮中提取异荭草素的方法 |
CN102743375A (zh) * | 2012-04-28 | 2012-10-24 | 苏州凯祥生物科技有限公司 | 异荭草素的用途及其药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0608546A2 (pt) | 2010-11-16 |
EP1863498A2 (en) | 2007-12-12 |
CA2601046A1 (en) | 2006-09-21 |
US20080214658A1 (en) | 2008-09-04 |
KR20070039406A (ko) | 2007-04-12 |
JP2008533131A (ja) | 2008-08-21 |
AU2006223734A1 (en) | 2006-09-21 |
AU2006223734B2 (en) | 2012-03-29 |
KR100720973B1 (ko) | 2007-05-22 |
WO2006098603A3 (en) | 2006-11-30 |
WO2006098603A2 (en) | 2006-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101203228A (zh) | 用于抗组胺的含异荭草素的组合物 | |
EP2086563B1 (en) | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria | |
US10555985B2 (en) | Pharmaceutical composition comprising refined Indigo naturalis extracts and the use thereof | |
EP1854446B1 (en) | Cold-water hop extract for use in prevention or alleviation of the symptoms of an allergic disease | |
CN107949394B (zh) | 黑豆叶提取物在制备用于预防或治疗代谢综合征的药物中的用途 | |
JP7446003B2 (ja) | マカ抽出物及びその用途 | |
Chigurupati et al. | Antioxidant and antidiabetic properties of Tamarindus indica leaf ethanolic extract from Malaysia | |
KR102378396B1 (ko) | 인디안구스베리 추출물과 새싹보리 추출물의 복합물(ib복합물)을 유효성분으로 포함하는 비만 및/또는 당뇨를 동반하는 대사증후군의 예방, 개선 치료용 조성물 | |
CN109793732B (zh) | 一种用于治疗绒毛膜癌的番荔枝种子提取物及其制备方法和应用 | |
KR102115669B1 (ko) | 벤조피렌의 생성은 억제되면서 사포닌은 증진되고 플라티코딘 d가 저감되는 흑도라지의 제조방법 | |
KR101051076B1 (ko) | 개복숭아를 포함하는 알레르기 치료용 조성물 및 이의 제조방법 | |
IL192791A (en) | Extract of xanthoceras sorbifolia bunge and extraction and uses thereof | |
KR101676297B1 (ko) | 이당류 소화효소활성 억제에 의한 혈당강하용 조성물 | |
EP2152283A1 (en) | Water soluble opuntia extracts for the inhibition of alpha-1-adrenergic receptors | |
KR20120037201A (ko) | 맥문동 종자 추출물을 포함하는 항비만 조성물 | |
KR20100101848A (ko) | 디아실 코에이:글리세롤 아실트랜스퍼라제 저해활성을 갖는감초 추출물, 이의 용매분획물 또는 이로부터 분리된 화합물을 포함하는 조성물 | |
CN110156784B (zh) | 一种吲哚型生物碱11-mt及其制备方法和应用 | |
KR101545495B1 (ko) | 삼백초 추출물과 그 유효성분인 쿼세틴을 함유하는 신경변성질환 예방 또는 치료용 약학조성물 및 건강기능식품, 그리고 삼백초 추출물 추출 방법 | |
CN108997468A (zh) | 蒲公英烷型三萜及其制备方法和用途 | |
KR102499893B1 (ko) | 삼백초 분획물을 포함하는 약학 조성물 및 이의 제조 방법 | |
CN113797240B (zh) | 一种白桐树总多酚提取物在制备抑制钙离子通道药物中的应用 | |
KR100816854B1 (ko) | 상황버섯 추출물을 이용한 알레르기 치료용 조성물 및 이의제조방법 | |
CN104817575B (zh) | 化合物、其提取方法、包含其的药物组合物及其用途 | |
KR101304293B1 (ko) | 쪽동백나무 조추출물, 이의 분획물 또는 그 분획물에서 분리된 생리활성물질을 유효성분으로 함유하는 식품조성물 또는 약학 조성물 | |
EP3342408A1 (en) | Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080618 |